Pfizer (PFE) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2026)
Pfizer (PFE) EPS (Weighted Average and Diluted) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (3y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
- |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
76.98% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
318.57% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
44.22% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-52.54% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
-14.16% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
26.25% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
-21.46% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
6.98% |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Mar 29, 2026 |
-21.46% |
| Sep 28, 2025 |
-25.67% |
| Jun 29, 2025 |
-33.45% |
| Mar 30, 2025 |
-27.60% |
| Sep 29, 2024 |
-18.29% |
| Jun 30, 2024 |
-78.60% |
| Mar 31, 2024 |
-13.84% |
| Oct 1, 2023 |
-66.61% |
| Jul 2, 2023 |
-12.88% |
| Apr 2, 2023 |
17.37% |
| Oct 2, 2022 |
3.55% |
| Jul 3, 2022 |
24.80% |
| Apr 3, 2022 |
26.30% |
| Oct 3, 2021 |
27.50% |
| Jul 4, 2021 |
16.21% |
| Apr 4, 2021 |
13.38% |
| Sep 27, 2020 |
-30.18% |
| Jun 28, 2020 |
6.73% |
| Mar 29, 2020 |
5.57% |
| Dec 31, 2019 |
-114.89% |
